Data with investigational Taxotere(R) regimens in the management of breast
cancer, across several disease stages, to be presented
BRIDGEWATER, N.J., Dec. 7 /PRNewswire-FirstCall/ -- Among the 62 oral
abstracts accepted for presentation at the 30th annual San Antonio Breast
Cancer Symposium (SABCS), six with Taxotere(R) (docetaxel) Injection
Concentrate investigational regimens will be presented in plenary sessions.
-- Plenary Lecture 1 on the opening day of the symposium will review data
for systemic adjuvant therapies being investigated for the treatment
of breast cancer.
"The worldwide overview: New results for systemic adjuvant therapies."
Peto R, Early Breast Cancer Trialists' Collaborative Group (EBCTCG),
University of Oxford, UK.
Thursday, December 13, 2007, 8:55 AM / Plenary lecture 1, Exhibit Hall D
-- The data from studies with Taxotere(R)-based regimens and
anthracycline-based regimens will be discussed through two
Abst 12: "Extended follow-up and analysis by age of the US Oncology
Adjuvant trial 9735." Jones S, et al; US Oncology Research, Inc., Houston,
Thursday, December 13, 2007, 9:45AM / Plenary lecture 1, Exhibit Hall D
This presentation includes the updated analysis (seven years median
follow-up) of a randomized trial comparing four cycles of a standard
anthracycline regimen, doxorubicin/cyclophosphamide (AC), to a non
anthracycline regimen, Taxotere(R)/cyclophosphamide (TC). New
findings regarding overall survival as well as the effect of age on
efficacy and safety will be presented.
Abst 13: "Role of anthracycline-based therapy in the adjuvant treatment
of breast cancer: efficacy analyses determined by molecular subtypes of the
disease." Slamon DJ, et al; Cancer International Research Group (CIRG),
Edmonton, AB, Canada.
Thursday, December 13, 2007, 10:00 AM / Plenary lecture 1, Exhibit Hall D
Based on survival data previously reported for the BCIRG 006 study,
this presentation will describe how molecular subtypes of early stage
breast cancer could be used to identify appropriate Taxotere(R)-based
therapies, either with or without anthracyclines, for women with HER2
-- Two other oral presentations will discuss studies involving
anthracycline regimens with or without Taxotere(R):
Abst 78: "Preliminary results of the UK Taxotere(R) as Adjuvant Chemotherapy (TACT) Trial." Ellis PA, et al; United Kingdom. Sunday, December 16, 2007, 10:45 AM / General session 7, Exhibit Hall D The UK TACT Trial, a large multicenter phase III randomized trial compared four cycles of sequential FEC* followed by four cycles of Taxotere(R) 100mg/m2 every three weeks to standard UK operable breast cancer adjuvant chemotherapy (FEC* or E-CMF*) for eight cycles.
*FEC : Fluorouracil 600mg/m squared, Epirubicin 60 mg/m2 , and Cyclophosphamide 600 mg/m2 q 3wk x 8
E-CMF: Epirubicin 100 mg/m2 q3wk x 4 followed by Cyclophosphamide100 mg/m2 PO d1-14 or 600 mg/m2 IV d1-8, Methotrexate 40 mg/m2, and Fluorouracil 600 mg/m2 q 4wk x 4
Abst 72: "Three-year follow-up of trastuzumab following adjuvant
chemotherapy in node positive HER2-positive breast cancer patients: results
of the PACS-04 trial." Spielmann M, et al.
Sunday, December 16, 2007, 9:15 AM / General session 7, Exhibit Hall D
Following the PACS-01 trial, the PACS-04 randomized, multicenter,
phase III trial is designed to evaluate concomitant Taxotere(R) and
epirubicin versus a standard French chemotherapy regimen (FEC 100*) in
the adjuvant treatment of node-positive early breast cancer, and the
sequential use or not of trastuzumab for HER2 positive patients.
*FEC100: Fluorouracil 500 mg/m2, Epirubicin 100 mg/m2, Cyclophosphamide 500 mg/m2 q 3 wk x 6
-- Taxotere(R) data in the neoadjuvant setting will also be presented:
Abst 79: "Evaluating the efficacy of capecitabine given concomitantly
or in sequence to epirubicin/cyclophosphamide >> docetaxel as neoadjuvant
treatment for primary breast cancer. First efficacy analysis of the GBG/AGO
intergroup-study "GeparQuattro" >>. von Minckwitz G, et al.
Sunday, December 16, 2007, 11:00 AM / General session 7, Exhibit Hall D
Prior to surgery, patients were treated with epirubicin and
cyclophosphamide followed by either Taxotere(R) alone
(100 mg/m squared), Taxotere(R) (75 mg/m squared) combined with
capecitabine (1800 mg/m squared), or Taxotere(R) (100mg/m2) followed
by capecitabine (1800mg/m2). The primary endpoint of the study is the
pathologic complete response at surgery.
-- Data from another investigational non-anthracycline Taxotere(R)-based
regimen will be presented from a study in patients with advanced HER2
positive breast cancer:
Abst 309: "Evaluation of trastuzumab, docetaxel and capecitabine as first- line therapy for HER2-positive locally advanced or metastatic breast cancer." Wardley A, et al.
Friday, December 14th, 2007 5:00-7:00 PM / Poster discussion session 3, Antibodies and Immunotherapy - Ballroom B
About Breast Cancer
Breast cancer is the most frequently diagnosed cancer in women. It is the second-leading cause of cancer death in women after lung cancer, and since 1990 is increasing predominantly in women 50 and over. It is the first cause of cancer mortality in women of 40 to 59 years old. According to the American Cancer Society, an estimated 200,000 women are diagnosed with breast cancer and approximately 40,000 women die of the disease in the United States every year. A woman is diagnosed with breast cancer in the United States every three minutes. The risk of a woman developing breast cancer during her lifetime is approximately 13 percent (about one in seven of all women in the United States). In the European Union, more than 191,000 new cases are diagnosed each year and more than 60,000 women will die. Of women with breast cancer, 20 to 25% of these women will have HER2 positive breast cancers. With earlier screening and diagnosis, early management of patients may offer better chances of survival.
Sanofi-aventis, a leading global pharmaceutical company, discovers, develops and distributes therapeutic solutions to improve the lives of everyone. Sanofi-aventis is listed in Paris (EURONEXT: SAN) and in New York (NYSE: SNY).
Forward-looking statements This press release contains forward-looking statements as defined in the Private Securities Litigation Reform Act of 1995, as amended. Forward-looking statements are statements that are not historical facts. These statements include financial projections and estimates and their underlying assumptions, statements regarding plans, objectives, intentions and expectations with respect to future events, operations, products and services, and statements regarding future performance. Forward-looking statements are generally identified by the words "expects," "anticipates," "believes," "intends," "estimates," "plans" and similar expressions. Although sanofi-aventis' management believes that the expectations reflected in such forward-looking statements are reasonable, investors are cautioned that forward-looking information and statements are subject to various risks and uncertainties, many of which are difficult to predict and generally beyond the control of sanofi-aventis, that could cause actual results and developments to differ materially from those expressed in, or implied or projected by, the forward- looking information and statements. These risks and uncertainties include those discussed or identified in the public filings with the SEC and the AMF made by sanofi-aventis, including those listed under "Risk Factors" and "Cautionary Statement Regarding Forward-Looking Statements" in sanofi-aventis' annual report on Form 20-F for the year ended December 31, 2006. Other than as required by applicable law, sanofi-aventis does not undertake any obligation to update or revise any forward-looking information or statements.
Contact: Noelle Boyd, sanofi-aventis, 908-981-6489
Copyright©2007 PR Newswire.
All rights reserved